| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 103 | 2024 | 12021 | 6.410 |
Why?
|
| Radiosurgery | 45 | 2024 | 1383 | 5.490 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 66 | 2024 | 5566 | 5.280 |
Why?
|
| Immunotherapy | 36 | 2024 | 3555 | 4.270 |
Why?
|
| Chemoradiotherapy | 28 | 2020 | 2027 | 3.530 |
Why?
|
| Small Cell Lung Carcinoma | 14 | 2023 | 417 | 2.590 |
Why?
|
| Radiotherapy, Intensity-Modulated | 25 | 2019 | 2163 | 2.490 |
Why?
|
| Esophageal Neoplasms | 23 | 2020 | 3234 | 2.310 |
Why?
|
| Radioimmunotherapy | 7 | 2024 | 128 | 2.270 |
Why?
|
| Neoplasms | 41 | 2024 | 15905 | 2.240 |
Why?
|
| Radiotherapy | 19 | 2021 | 1858 | 2.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 9 | 2022 | 1094 | 2.060 |
Why?
|
| Antineoplastic Agents, Immunological | 11 | 2021 | 1336 | 1.970 |
Why?
|
| Proton Therapy | 12 | 2024 | 1635 | 1.900 |
Why?
|
| Tumor Escape | 3 | 2021 | 247 | 1.870 |
Why?
|
| Lymphopenia | 6 | 2022 | 211 | 1.850 |
Why?
|
| Tumor Microenvironment | 14 | 2024 | 3031 | 1.850 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 30 | 2022 | 2452 | 1.790 |
Why?
|
| Radiotherapy Dosage | 37 | 2021 | 3999 | 1.700 |
Why?
|
| Nanoparticles | 5 | 2024 | 585 | 1.640 |
Why?
|
| Tomography, Spiral Computed | 8 | 2012 | 128 | 1.580 |
Why?
|
| Radiation Injuries | 23 | 2018 | 1471 | 1.560 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2023 | 39 | 1.500 |
Why?
|
| Radiation Dosage | 10 | 2021 | 1043 | 1.460 |
Why?
|
| Radiation Tolerance | 8 | 2019 | 637 | 1.430 |
Why?
|
| Ipilimumab | 10 | 2024 | 759 | 1.300 |
Why?
|
| Humans | 219 | 2024 | 270457 | 1.240 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2019 | 67 | 1.230 |
Why?
|
| Adenocarcinoma | 22 | 2022 | 7884 | 1.230 |
Why?
|
| Neoplasms, Second Primary | 7 | 2023 | 1387 | 1.210 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2019 | 103 | 1.180 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2024 | 366 | 1.120 |
Why?
|
| Combined Modality Therapy | 29 | 2024 | 9041 | 1.070 |
Why?
|
| Radiation Oncology | 8 | 2022 | 558 | 1.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2023 | 3398 | 1.050 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2024 | 255 | 1.040 |
Why?
|
| Antineoplastic Agents | 14 | 2022 | 14623 | 0.990 |
Why?
|
| Animals | 44 | 2024 | 62021 | 0.990 |
Why?
|
| Mars | 2 | 2022 | 5 | 0.980 |
Why?
|
| Aged | 94 | 2024 | 73175 | 0.960 |
Why?
|
| Mice | 31 | 2024 | 35592 | 0.950 |
Why?
|
| Piperidines | 2 | 2020 | 1086 | 0.950 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2019 | 10384 | 0.920 |
Why?
|
| Cranial Irradiation | 4 | 2018 | 322 | 0.920 |
Why?
|
| c-Mer Tyrosine Kinase | 2 | 2024 | 28 | 0.910 |
Why?
|
| Female | 115 | 2024 | 148644 | 0.900 |
Why?
|
| Radiotherapy, Conformal | 10 | 2014 | 898 | 0.890 |
Why?
|
| Tumor Burden | 13 | 2022 | 2031 | 0.890 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2024 | 1655 | 0.890 |
Why?
|
| Aged, 80 and over | 57 | 2024 | 30936 | 0.880 |
Why?
|
| Liver Neoplasms | 7 | 2023 | 4814 | 0.880 |
Why?
|
| Organs at Risk | 8 | 2020 | 559 | 0.850 |
Why?
|
| Esophagitis | 5 | 2019 | 201 | 0.850 |
Why?
|
| B7-H1 Antigen | 4 | 2021 | 1081 | 0.850 |
Why?
|
| Male | 109 | 2024 | 128105 | 0.820 |
Why?
|
| Treatment Outcome | 53 | 2024 | 33708 | 0.810 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 125 | 0.810 |
Why?
|
| Brachytherapy | 6 | 2010 | 1005 | 0.790 |
Why?
|
| Middle Aged | 88 | 2024 | 90100 | 0.790 |
Why?
|
| Radiation Exposure | 2 | 2022 | 71 | 0.780 |
Why?
|
| Brain Neoplasms | 13 | 2023 | 4955 | 0.770 |
Why?
|
| Quinazolines | 4 | 2015 | 956 | 0.770 |
Why?
|
| Cell Line, Tumor | 19 | 2024 | 14836 | 0.750 |
Why?
|
| Space Flight | 2 | 2022 | 126 | 0.740 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2013 | 427 | 0.730 |
Why?
|
| Carcinoma, Squamous Cell | 13 | 2017 | 5585 | 0.730 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2020 | 62 | 0.710 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 58 | 0.710 |
Why?
|
| Lung | 17 | 2023 | 3289 | 0.700 |
Why?
|
| Oxadiazoles | 1 | 2020 | 60 | 0.690 |
Why?
|
| Adult | 67 | 2024 | 81754 | 0.680 |
Why?
|
| Immune Tolerance | 3 | 2019 | 423 | 0.680 |
Why?
|
| Immunity | 3 | 2020 | 355 | 0.670 |
Why?
|
| Thoracic Neoplasms | 5 | 2020 | 352 | 0.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 16646 | 0.670 |
Why?
|
| Neoplasm Metastasis | 14 | 2024 | 5309 | 0.670 |
Why?
|
| ErbB Receptors | 5 | 2022 | 2376 | 0.660 |
Why?
|
| Skin Neoplasms | 4 | 2023 | 4887 | 0.650 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2016 | 743 | 0.640 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2018 | 19 | 0.630 |
Why?
|
| Melanoma | 5 | 2023 | 5595 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 8 | 2022 | 4476 | 0.620 |
Why?
|
| Receptors, OX40 | 1 | 2018 | 51 | 0.610 |
Why?
|
| Dose-Response Relationship, Radiation | 10 | 2021 | 751 | 0.600 |
Why?
|
| MicroRNAs | 7 | 2019 | 2890 | 0.600 |
Why?
|
| Oximes | 1 | 2019 | 191 | 0.590 |
Why?
|
| Antigens, CD | 1 | 2022 | 1418 | 0.580 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2019 | 714 | 0.580 |
Why?
|
| Retrospective Studies | 50 | 2024 | 39751 | 0.570 |
Why?
|
| Heart | 6 | 2020 | 1195 | 0.560 |
Why?
|
| Thoracic Wall | 4 | 2016 | 188 | 0.550 |
Why?
|
| Thorax | 1 | 2018 | 232 | 0.550 |
Why?
|
| Photons | 4 | 2024 | 536 | 0.550 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 678 | 0.540 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2021 | 5407 | 0.530 |
Why?
|
| Pneumonectomy | 7 | 2021 | 862 | 0.520 |
Why?
|
| Energy Metabolism | 2 | 2023 | 997 | 0.510 |
Why?
|
| Positron-Emission Tomography | 9 | 2014 | 2196 | 0.510 |
Why?
|
| Interferon Type I | 1 | 2016 | 282 | 0.500 |
Why?
|
| Galectin 1 | 1 | 2014 | 20 | 0.490 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2021 | 7784 | 0.480 |
Why?
|
| Neoplasm Staging | 29 | 2023 | 13998 | 0.480 |
Why?
|
| Survival Rate | 19 | 2020 | 12513 | 0.470 |
Why?
|
| Survival Analysis | 18 | 2024 | 9294 | 0.470 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2023 | 1135 | 0.460 |
Why?
|
| Radiation Pneumonitis | 6 | 2018 | 313 | 0.460 |
Why?
|
| Immunologic Factors | 2 | 2020 | 671 | 0.450 |
Why?
|
| Immunity, Innate | 1 | 2018 | 700 | 0.450 |
Why?
|
| Glioblastoma | 3 | 2009 | 1773 | 0.450 |
Why?
|
| Clinical Trials as Topic | 7 | 2021 | 3844 | 0.450 |
Why?
|
| Prospective Studies | 15 | 2022 | 13383 | 0.440 |
Why?
|
| Mitochondria | 1 | 2020 | 1300 | 0.440 |
Why?
|
| Pyrimidines | 2 | 2020 | 3662 | 0.430 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 654 | 0.420 |
Why?
|
| Signal Transduction | 6 | 2020 | 12104 | 0.410 |
Why?
|
| Patient Safety | 1 | 2018 | 651 | 0.410 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2012 | 18 | 0.400 |
Why?
|
| Brachial Plexus | 1 | 2012 | 47 | 0.390 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 321 | 0.390 |
Why?
|
| Positron Emission Tomography Computed Tomography | 5 | 2023 | 880 | 0.390 |
Why?
|
| Lymphocyte Count | 4 | 2020 | 485 | 0.380 |
Why?
|
| Thoracic Vertebrae | 2 | 2010 | 200 | 0.380 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 396 | 0.380 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2020 | 1017 | 0.380 |
Why?
|
| Lymph Nodes | 6 | 2023 | 3070 | 0.370 |
Why?
|
| Prostatic Neoplasms | 6 | 2024 | 5860 | 0.360 |
Why?
|
| Apoptosis | 3 | 2014 | 7753 | 0.360 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 15191 | 0.350 |
Why?
|
| Immunologic Memory | 2 | 2022 | 380 | 0.350 |
Why?
|
| Rad51 Recombinase | 2 | 2012 | 125 | 0.350 |
Why?
|
| Radiodermatitis | 1 | 2010 | 79 | 0.350 |
Why?
|
| Esophagectomy | 7 | 2013 | 946 | 0.340 |
Why?
|
| Spinal Diseases | 1 | 2010 | 131 | 0.340 |
Why?
|
| Sulfonamides | 1 | 2019 | 1933 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 2647 | 0.330 |
Why?
|
| Mutation | 4 | 2015 | 15908 | 0.330 |
Why?
|
| Chest Pain | 1 | 2010 | 172 | 0.330 |
Why?
|
| Aorta | 1 | 2013 | 671 | 0.320 |
Why?
|
| Whole-Body Irradiation | 4 | 2021 | 323 | 0.320 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2011 | 231 | 0.320 |
Why?
|
| T-Lymphocytes | 5 | 2023 | 3944 | 0.320 |
Why?
|
| Radiopharmaceuticals | 2 | 2014 | 1341 | 0.320 |
Why?
|
| Nomograms | 3 | 2019 | 313 | 0.310 |
Why?
|
| Intestine, Small | 1 | 2012 | 520 | 0.310 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 1260 | 0.310 |
Why?
|
| Insurance Coverage | 3 | 2020 | 274 | 0.310 |
Why?
|
| Treatment Failure | 8 | 2020 | 1425 | 0.300 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2023 | 1840 | 0.300 |
Why?
|
| Disease-Free Survival | 15 | 2024 | 10262 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 7 | 2013 | 5225 | 0.290 |
Why?
|
| Scalp | 2 | 2006 | 155 | 0.290 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 563 | 0.290 |
Why?
|
| Chemoradiotherapy, Adjuvant | 4 | 2014 | 562 | 0.290 |
Why?
|
| Radiobiology | 2 | 2022 | 56 | 0.290 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2008 | 303 | 0.290 |
Why?
|
| Young Adult | 13 | 2021 | 22152 | 0.280 |
Why?
|
| Regression Analysis | 6 | 2021 | 1570 | 0.280 |
Why?
|
| Phantoms, Imaging | 2 | 2021 | 1330 | 0.270 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 620 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2020 | 9041 | 0.260 |
Why?
|
| Iran | 2 | 2022 | 76 | 0.250 |
Why?
|
| Breast Neoplasms | 7 | 2014 | 16184 | 0.250 |
Why?
|
| Radiometry | 5 | 2018 | 1017 | 0.250 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2021 | 211 | 0.250 |
Why?
|
| Protons | 3 | 2023 | 482 | 0.250 |
Why?
|
| Immune System | 2 | 2018 | 275 | 0.240 |
Why?
|
| Sarcoma, Ewing | 1 | 2009 | 429 | 0.240 |
Why?
|
| India | 2 | 2021 | 313 | 0.230 |
Why?
|
| Yttrium Radioisotopes | 1 | 2006 | 210 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 2392 | 0.230 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 7371 | 0.230 |
Why?
|
| Proto-Oncogenes | 1 | 2024 | 208 | 0.220 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2015 | 398 | 0.220 |
Why?
|
| United States | 11 | 2021 | 15856 | 0.220 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 3655 | 0.220 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 1556 | 0.210 |
Why?
|
| STAT6 Transcription Factor | 1 | 2023 | 68 | 0.210 |
Why?
|
| Activins | 1 | 2022 | 94 | 0.210 |
Why?
|
| HLA-A2 Antigen | 1 | 2023 | 172 | 0.210 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 1388 | 0.210 |
Why?
|
| Particle Accelerators | 4 | 2011 | 362 | 0.210 |
Why?
|
| Radiography | 5 | 2021 | 1988 | 0.210 |
Why?
|
| Time Factors | 13 | 2021 | 12991 | 0.200 |
Why?
|
| Antigen Presentation | 1 | 2023 | 286 | 0.200 |
Why?
|
| Prostheses and Implants | 1 | 2004 | 294 | 0.200 |
Why?
|
| Prognosis | 15 | 2021 | 22475 | 0.200 |
Why?
|
| Palliative Care | 3 | 2020 | 2173 | 0.200 |
Why?
|
| Lymphocytes | 4 | 2022 | 1272 | 0.200 |
Why?
|
| Enthesopathy | 1 | 2021 | 3 | 0.200 |
Why?
|
| X-Rays | 3 | 2021 | 151 | 0.200 |
Why?
|
| Industry | 1 | 2021 | 50 | 0.190 |
Why?
|
| Proportional Hazards Models | 11 | 2020 | 5104 | 0.190 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2022 | 247 | 0.190 |
Why?
|
| Feasibility Studies | 6 | 2015 | 2364 | 0.190 |
Why?
|
| Inflammasomes | 1 | 2023 | 174 | 0.190 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 147 | 0.190 |
Why?
|
| Lymphatic Metastasis | 6 | 2023 | 4956 | 0.190 |
Why?
|
| Stearic Acids | 1 | 2020 | 7 | 0.190 |
Why?
|
| Bone Marrow | 1 | 2009 | 2439 | 0.190 |
Why?
|
| Urethral Neoplasms | 1 | 2021 | 61 | 0.190 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 95 | 0.180 |
Why?
|
| Patient Selection | 2 | 2020 | 2029 | 0.180 |
Why?
|
| Interleukin-2 | 1 | 2024 | 889 | 0.180 |
Why?
|
| Tumor Hypoxia | 1 | 2020 | 24 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2020 | 22 | 0.180 |
Why?
|
| Receptors, Immunologic | 1 | 2022 | 314 | 0.180 |
Why?
|
| Smad1 Protein | 1 | 2020 | 35 | 0.180 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 58 | 0.180 |
Why?
|
| Follistatin | 1 | 2020 | 55 | 0.180 |
Why?
|
| Conflict of Interest | 1 | 2021 | 92 | 0.180 |
Why?
|
| Liver | 5 | 2016 | 3083 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2014 | 2270 | 0.180 |
Why?
|
| Cell Proliferation | 5 | 2018 | 7242 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 381 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2021 | 118 | 0.170 |
Why?
|
| RNA, Long Noncoding | 2 | 2018 | 619 | 0.170 |
Why?
|
| Up-Regulation | 2 | 2019 | 2421 | 0.170 |
Why?
|
| Osteoarthritis | 1 | 2021 | 112 | 0.170 |
Why?
|
| Vaginal Neoplasms | 1 | 2021 | 152 | 0.170 |
Why?
|
| Mice, 129 Strain | 1 | 2020 | 160 | 0.170 |
Why?
|
| Models, Theoretical | 2 | 2021 | 806 | 0.170 |
Why?
|
| Research Personnel | 1 | 2021 | 168 | 0.170 |
Why?
|
| Esophagogastric Junction | 3 | 2012 | 553 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 153 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 7093 | 0.170 |
Why?
|
| Policy | 1 | 2019 | 53 | 0.170 |
Why?
|
| Diabetes Complications | 2 | 2012 | 306 | 0.170 |
Why?
|
| Prostatectomy | 1 | 2024 | 1003 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6256 | 0.160 |
Why?
|
| Pleural Neoplasms | 2 | 2014 | 485 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 3 | 2022 | 966 | 0.160 |
Why?
|
| Risk Factors | 9 | 2014 | 17849 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 154 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 272 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 4960 | 0.160 |
Why?
|
| Mesothelioma | 2 | 2014 | 558 | 0.160 |
Why?
|
| Myositis | 1 | 1999 | 86 | 0.160 |
Why?
|
| Capecitabine | 1 | 2019 | 390 | 0.160 |
Why?
|
| United States National Aeronautics and Space Administration | 1 | 2018 | 21 | 0.150 |
Why?
|
| Glycosylation | 1 | 2018 | 229 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 307 | 0.150 |
Why?
|
| Kynurenine | 1 | 2018 | 67 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 2 | 2016 | 1322 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 1052 | 0.150 |
Why?
|
| Tryptophan | 1 | 2018 | 143 | 0.150 |
Why?
|
| Fluorouracil | 2 | 2019 | 1989 | 0.150 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 594 | 0.150 |
Why?
|
| Metastasectomy | 1 | 2020 | 209 | 0.150 |
Why?
|
| Urogenital Neoplasms | 1 | 2018 | 115 | 0.150 |
Why?
|
| Incidence | 7 | 2018 | 5812 | 0.150 |
Why?
|
| Obesity | 1 | 2010 | 2911 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2000 | 402 | 0.150 |
Why?
|
| Neoplasms, Experimental | 3 | 2021 | 785 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 3343 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 1111 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1077 | 0.150 |
Why?
|
| Medicaid | 1 | 2020 | 305 | 0.140 |
Why?
|
| Re-Irradiation | 1 | 2018 | 166 | 0.140 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2018 | 120 | 0.140 |
Why?
|
| Spinal Cord | 2 | 2010 | 720 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 4 | 2020 | 4140 | 0.140 |
Why?
|
| Carboplatin | 2 | 2017 | 879 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 262 | 0.140 |
Why?
|
| Macrophages | 1 | 2023 | 1351 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2018 | 736 | 0.140 |
Why?
|
| Precision Medicine | 2 | 2024 | 1207 | 0.140 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 622 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 686 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 4323 | 0.130 |
Why?
|
| Neutrophils | 2 | 2018 | 867 | 0.130 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 670 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 2058 | 0.130 |
Why?
|
| Models, Biological | 3 | 2020 | 3196 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2015 | 41 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3914 | 0.130 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 242 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 563 | 0.130 |
Why?
|
| CD8 Antigens | 1 | 2015 | 173 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2019 | 827 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2012 | 3592 | 0.120 |
Why?
|
| Mentors | 1 | 2017 | 210 | 0.120 |
Why?
|
| Retreatment | 3 | 2010 | 447 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 5774 | 0.120 |
Why?
|
| Neoplasm Grading | 3 | 2014 | 1821 | 0.120 |
Why?
|
| Cisplatin | 2 | 2020 | 2497 | 0.120 |
Why?
|
| Medical Oncology | 2 | 2021 | 1463 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2010 | 1573 | 0.120 |
Why?
|
| Cytokines | 1 | 2023 | 2824 | 0.120 |
Why?
|
| Lymphatic Irradiation | 2 | 2012 | 139 | 0.110 |
Why?
|
| Cancer Pain | 1 | 2019 | 344 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 102 | 0.110 |
Why?
|
| Algorithms | 3 | 2011 | 3919 | 0.110 |
Why?
|
| Pleura | 1 | 2014 | 130 | 0.110 |
Why?
|
| Liposomes | 1 | 2015 | 705 | 0.110 |
Why?
|
| Biopsy | 3 | 2018 | 3387 | 0.110 |
Why?
|
| ROC Curve | 3 | 2021 | 1249 | 0.110 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 550 | 0.110 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 61 | 0.110 |
Why?
|
| Paclitaxel | 2 | 2017 | 2101 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 278 | 0.100 |
Why?
|
| Cesium Radioisotopes | 1 | 2012 | 38 | 0.100 |
Why?
|
| Internet | 1 | 2017 | 704 | 0.100 |
Why?
|
| Breast Neoplasms, Male | 1 | 2014 | 232 | 0.100 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 231 | 0.100 |
Why?
|
| Chromosomal Instability | 1 | 2013 | 229 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2024 | 3993 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2014 | 234 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2013 | 329 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2023 | 1814 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2020 | 9466 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2012 | 128 | 0.100 |
Why?
|
| Transcriptome | 1 | 2020 | 1954 | 0.100 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 527 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 1430 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 600 | 0.100 |
Why?
|
| Intestinal Polyposis | 1 | 2011 | 30 | 0.090 |
Why?
|
| Clinical Medicine | 1 | 2011 | 27 | 0.090 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2011 | 59 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 700 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 1002 | 0.090 |
Why?
|
| Heterozygote | 1 | 2014 | 1056 | 0.090 |
Why?
|
| Biophysical Phenomena | 1 | 2010 | 117 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 1946 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 318 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 3525 | 0.090 |
Why?
|
| Drug Eruptions | 1 | 2013 | 271 | 0.090 |
Why?
|
| Back Pain | 1 | 2010 | 63 | 0.090 |
Why?
|
| Anilides | 1 | 2013 | 294 | 0.090 |
Why?
|
| Basal Ganglia | 1 | 2010 | 62 | 0.090 |
Why?
|
| Organ Size | 1 | 2012 | 692 | 0.090 |
Why?
|
| Logistic Models | 3 | 2012 | 3441 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 2204 | 0.090 |
Why?
|
| Axilla | 2 | 2010 | 933 | 0.090 |
Why?
|
| Acute Disease | 2 | 2018 | 2491 | 0.090 |
Why?
|
| Thiourea | 1 | 2009 | 20 | 0.090 |
Why?
|
| Cicatrix | 1 | 2012 | 187 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 3700 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 5142 | 0.090 |
Why?
|
| Abdomen | 1 | 2012 | 349 | 0.090 |
Why?
|
| Comet Assay | 1 | 2009 | 57 | 0.090 |
Why?
|
| Metals | 1 | 2010 | 148 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 5071 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 1121 | 0.090 |
Why?
|
| Technology, Radiologic | 1 | 2010 | 78 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2018 | 4648 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2013 | 554 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2020 | 6776 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2011 | 226 | 0.080 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 1430 | 0.080 |
Why?
|
| Ablation Techniques | 1 | 2011 | 149 | 0.080 |
Why?
|
| Disease Progression | 5 | 2019 | 6842 | 0.080 |
Why?
|
| Quinolines | 1 | 2013 | 400 | 0.080 |
Why?
|
| Stomach Neoplasms | 2 | 2012 | 2258 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2017 | 1442 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 1122 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 1006 | 0.080 |
Why?
|
| Sarcoma | 1 | 2020 | 1836 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 1469 | 0.080 |
Why?
|
| Safety | 1 | 2010 | 464 | 0.080 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2009 | 34 | 0.080 |
Why?
|
| Occupational Exposure | 1 | 2010 | 248 | 0.080 |
Why?
|
| Oncology Service, Hospital | 1 | 2008 | 49 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2014 | 1158 | 0.080 |
Why?
|
| Growth Substances | 2 | 2000 | 326 | 0.080 |
Why?
|
| Metformin | 1 | 2012 | 394 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 725 | 0.080 |
Why?
|
| Zebrafish Proteins | 2 | 2000 | 155 | 0.080 |
Why?
|
| Clavicle | 1 | 2008 | 67 | 0.080 |
Why?
|
| Diarrhea | 1 | 2012 | 724 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 600 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2014 | 4329 | 0.080 |
Why?
|
| Prevalence | 2 | 2016 | 3357 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2012 | 512 | 0.070 |
Why?
|
| Artifacts | 1 | 2010 | 538 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1580 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2010 | 286 | 0.070 |
Why?
|
| Oncogene Proteins | 2 | 2000 | 367 | 0.070 |
Why?
|
| Mastectomy | 1 | 2014 | 1553 | 0.070 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2009 | 327 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 675 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2013 | 749 | 0.070 |
Why?
|
| CD3 Complex | 2 | 2018 | 320 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 1900 | 0.070 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2011 | 481 | 0.070 |
Why?
|
| Cetuximab | 2 | 2023 | 474 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 1792 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2021 | 729 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 372 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2664 | 0.070 |
Why?
|
| Lymph Node Excision | 3 | 2021 | 2056 | 0.070 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2006 | 33 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 1585 | 0.070 |
Why?
|
| Immunomodulation | 2 | 2019 | 256 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 608 | 0.060 |
Why?
|
| Pyridines | 1 | 2013 | 1311 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 885 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1578 | 0.060 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2005 | 67 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2011 | 1743 | 0.060 |
Why?
|
| Cell Movement | 1 | 2013 | 2472 | 0.060 |
Why?
|
| Microspheres | 1 | 2006 | 238 | 0.060 |
Why?
|
| Proteomics | 1 | 2012 | 1425 | 0.060 |
Why?
|
| Gold Radioisotopes | 1 | 2004 | 6 | 0.060 |
Why?
|
| Health Personnel | 1 | 2010 | 656 | 0.060 |
Why?
|
| DNA Damage | 1 | 2013 | 1982 | 0.060 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 353 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 4044 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 2512 | 0.060 |
Why?
|
| Biomarkers | 3 | 2023 | 5054 | 0.060 |
Why?
|
| Piperazines | 2 | 2012 | 2145 | 0.060 |
Why?
|
| Silver | 1 | 2004 | 39 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2012 | 4947 | 0.060 |
Why?
|
| Linear Models | 2 | 2021 | 1095 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2008 | 627 | 0.060 |
Why?
|
| Genotype | 3 | 2020 | 4251 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 6188 | 0.060 |
Why?
|
| Eye | 1 | 2005 | 283 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 907 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 2197 | 0.060 |
Why?
|
| Stereotaxic Techniques | 1 | 2004 | 184 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1046 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2010 | 1320 | 0.060 |
Why?
|
| Hemangiosarcoma | 1 | 2006 | 238 | 0.050 |
Why?
|
| Adolescent | 7 | 2023 | 32671 | 0.050 |
Why?
|
| Hypertension | 1 | 2013 | 1596 | 0.050 |
Why?
|
| Relative Biological Effectiveness | 1 | 2004 | 227 | 0.050 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2014 | 231 | 0.050 |
Why?
|
| CD47 Antigen | 1 | 2022 | 28 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2011 | 1695 | 0.050 |
Why?
|
| Stents | 1 | 2009 | 1003 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2010 | 2239 | 0.050 |
Why?
|
| Biomarkers, Tumor | 4 | 2016 | 10697 | 0.050 |
Why?
|
| Age Factors | 3 | 2019 | 5462 | 0.050 |
Why?
|
| V(D)J Recombination | 1 | 2021 | 9 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 4951 | 0.050 |
Why?
|
| Breast | 1 | 2008 | 1366 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2007 | 1049 | 0.050 |
Why?
|
| Salvage Therapy | 3 | 2018 | 2123 | 0.050 |
Why?
|
| Headache | 1 | 2022 | 175 | 0.050 |
Why?
|
| Radiographic Image Enhancement | 1 | 2004 | 410 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 135 | 0.050 |
Why?
|
| Molecular Imaging | 1 | 2023 | 186 | 0.050 |
Why?
|
| Taxoids | 2 | 2017 | 1016 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2022 | 236 | 0.050 |
Why?
|
| Pelvis | 2 | 2001 | 383 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2018 | 3045 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2021 | 120 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2020 | 64 | 0.050 |
Why?
|
| Strontium Radioisotopes | 1 | 2000 | 31 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2014 | 5438 | 0.040 |
Why?
|
| Texas | 3 | 2021 | 6432 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2000 | 7273 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 260 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2021 | 2234 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2000 | 2618 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2013 | 5672 | 0.040 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2019 | 38 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 181 | 0.040 |
Why?
|
| SEER Program | 2 | 2014 | 1049 | 0.040 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2013 | 340 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 256 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2021 | 427 | 0.040 |
Why?
|
| Glioma | 1 | 2010 | 1977 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 3341 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 255 | 0.040 |
Why?
|
| Extraterrestrial Environment | 1 | 2018 | 9 | 0.040 |
Why?
|
| CD11c Antigen | 1 | 2018 | 56 | 0.040 |
Why?
|
| CD11b Antigen | 1 | 2018 | 64 | 0.040 |
Why?
|
| Muscles | 1 | 1999 | 456 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 1998 | 105 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2019 | 327 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2001 | 325 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 190 | 0.040 |
Why?
|
| RNA Editing | 1 | 2018 | 97 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2000 | 526 | 0.040 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2019 | 116 | 0.040 |
Why?
|
| Swine | 1 | 2021 | 1607 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 1689 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 1109 | 0.040 |
Why?
|
| Immobilization | 2 | 2010 | 91 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 129 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2003 | 1066 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2018 | 247 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 311 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2018 | 726 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2001 | 604 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1402 | 0.030 |
Why?
|
| Oncogenes | 1 | 2000 | 700 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2016 | 84 | 0.030 |
Why?
|
| Fatigue | 1 | 2022 | 1278 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 524 | 0.030 |
Why?
|
| Quality Control | 2 | 2010 | 463 | 0.030 |
Why?
|
| Protein Binding | 1 | 2022 | 3486 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 3242 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 481 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 490 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2327 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1998 | 658 | 0.030 |
Why?
|
| Quality of Life | 2 | 2021 | 4773 | 0.030 |
Why?
|
| Kinetics | 1 | 2018 | 2220 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 713 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1296 | 0.030 |
Why?
|
| Phenotype | 2 | 2018 | 6497 | 0.030 |
Why?
|
| Recurrence | 1 | 2023 | 4877 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 1485 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2021 | 1185 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 609 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 138 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2014 | 6204 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2178 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2017 | 396 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2014 | 167 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 372 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 284 | 0.030 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2013 | 31 | 0.030 |
Why?
|
| Troponin I | 1 | 2014 | 130 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2000 | 1626 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 5250 | 0.030 |
Why?
|
| Informed Consent | 1 | 2016 | 415 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 1718 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 788 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2014 | 314 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 716 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2391 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 824 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2013 | 102 | 0.030 |
Why?
|
| Brain | 1 | 2005 | 4209 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2355 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1999 | 998 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2012 | 150 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2014 | 261 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 2299 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 327 | 0.020 |
Why?
|
| Systems Integration | 1 | 2012 | 79 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2018 | 1110 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2012 | 162 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 319 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2022 | 4121 | 0.020 |
Why?
|
| Wisconsin | 1 | 2011 | 27 | 0.020 |
Why?
|
| Maryland | 1 | 2011 | 50 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2011 | 38 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 316 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2012 | 306 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2014 | 728 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1200 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2011 | 206 | 0.020 |
Why?
|
| Phthalazines | 1 | 2012 | 263 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 445 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2012 | 293 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4222 | 0.020 |
Why?
|
| Physics | 1 | 2010 | 44 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 667 | 0.020 |
Why?
|
| CCN Intercellular Signaling Proteins | 2 | 2000 | 5 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 704 | 0.020 |
Why?
|
| Wnt1 Protein | 2 | 2000 | 100 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2012 | 474 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 1270 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2017 | 1324 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 7897 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1310 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 485 | 0.020 |
Why?
|
| Proteome | 1 | 2012 | 571 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 678 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 842 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 445 | 0.020 |
Why?
|
| Propensity Score | 1 | 2011 | 769 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 2321 | 0.020 |
Why?
|
| Liver Regeneration | 1 | 2008 | 133 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 1939 | 0.020 |
Why?
|
| Wnt Proteins | 2 | 2000 | 384 | 0.020 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2008 | 135 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3061 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 368 | 0.020 |
Why?
|
| Indoles | 1 | 2012 | 1028 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1999 | 2432 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2009 | 655 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3650 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 1710 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 1565 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5921 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 745 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2009 | 951 | 0.010 |
Why?
|
| Transfection | 2 | 2000 | 3118 | 0.010 |
Why?
|
| Certification | 1 | 2004 | 109 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 1573 | 0.010 |
Why?
|
| Neck | 1 | 2006 | 394 | 0.010 |
Why?
|
| Smoking | 1 | 2012 | 2549 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2000 | 4569 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 588 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2012 | 6394 | 0.010 |
Why?
|
| Respiration | 1 | 2004 | 464 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2000 | 6685 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2008 | 1239 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 5159 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 195 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 631 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 1998 | 43 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 2394 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 426 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 1758 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 1431 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 938 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 909 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 876 | 0.010 |
Why?
|
| DNA Repair | 1 | 2004 | 1910 | 0.010 |
Why?
|
| beta Catenin | 1 | 2000 | 688 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1110 | 0.010 |
Why?
|
| Binding Sites | 1 | 2000 | 2255 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 3028 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2000 | 1656 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1998 | 1280 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2000 | 3213 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 5339 | 0.010 |
Why?
|
| Kidney | 1 | 2000 | 2121 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 5758 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2000 | 2448 | 0.010 |
Why?
|
| Rats | 1 | 2000 | 6522 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 4136 | 0.000 |
Why?
|
| Child | 1 | 2010 | 30496 | 0.000 |
Why?
|